Lantheus Holdings Inc (NASDAQ:LNTH) CFO John W. Crowley sold 3,866 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $23.52, for a total transaction of $90,928.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Lantheus Holdings Inc (NASDAQ:LNTH) traded up $0.20 during midday trading on Friday, hitting $22.60. 214,900 shares of the stock traded hands, compared to its average volume of 298,392. Lantheus Holdings Inc has a 52-week low of $7.95 and a 52-week high of $24.10. The firm has a market capitalization of $844.82 and a price-to-earnings ratio of 28.25. The company has a quick ratio of 2.46, a current ratio of 2.96 and a debt-to-equity ratio of -3.41.
Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.04. Lantheus had a net margin of 9.59% and a negative return on equity of 46.45%. The firm had revenue of $79.94 million for the quarter, compared to analyst estimates of $77.18 million. During the same quarter in the prior year, the business earned $0.15 earnings per share. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. sell-side analysts forecast that Lantheus Holdings Inc will post 1.05 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. bought a new stake in shares of Lantheus during the second quarter worth about $770,000. First Trust Advisors LP increased its position in shares of Lantheus by 24.8% during the second quarter. First Trust Advisors LP now owns 23,468 shares of the medical equipment provider’s stock worth $414,000 after acquiring an additional 4,669 shares in the last quarter. Rhumbline Advisers bought a new stake in shares of Lantheus during the second quarter worth about $903,000. Bank of New York Mellon Corp increased its position in shares of Lantheus by 434.6% during the second quarter. Bank of New York Mellon Corp now owns 366,048 shares of the medical equipment provider’s stock worth $6,460,000 after acquiring an additional 297,575 shares in the last quarter. Finally, Legal & General Group Plc bought a new stake in shares of Lantheus during the second quarter worth about $908,000. Hedge funds and other institutional investors own 91.91% of the company’s stock.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.